Pseudo-mannosylated DC-SIGN Ligands as potential adjuvants for HIV vaccines

Angela Berzi, Norbert Varga, Sara Sattin, Patrizio Antonazzo, Mara Biasin, Irene Cetin, Daria Trabattoni, Anna Bernardi, Mario Clerici

Research output: Contribution to journalArticlepeer-review


The development of new and effective adjuvants may play a fundamental role in improving HIV vaccine efficacy. New classes of vaccine adjuvants activate innate immunity receptors, notably toll like receptors (TLRs). Adjuvants targeting the C-Type lectin receptor DC-SIGN may be alternative or complementary to adjuvants based on TRL activation. Herein we evaluate the ability of the glycomimetic DC-SIGN ligand Polyman 19 (PM 19) to modulate innate immune responses. Results showed that PM 19 alone, or in combination with TLR agonists, induces the expression of cytokines, β chemokines and co-stimulatory molecules that may, in turn, modulate adaptive immunity and exert anti-viral effects. These results indicate that the suitability of this compound as a vaccine adjuvant should be further evaluated.

Original languageEnglish
Pages (from-to)391-403
Number of pages13
Issue number2
Publication statusPublished - 2014


  • Adjuvant
  • Glycomimetic compounds
  • HIV-1
  • Innate immunity
  • Vaccine

ASJC Scopus subject areas

  • Infectious Diseases
  • Virology


Dive into the research topics of 'Pseudo-mannosylated DC-SIGN Ligands as potential adjuvants for HIV vaccines'. Together they form a unique fingerprint.

Cite this